These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 26113432)

  • 1. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans.
    Backus LI; Belperio PS; Shahoumian TA; Loomis TP; Mole LA
    Aliment Pharmacol Ther; 2015 Sep; 42(5):559-73. PubMed ID: 26113432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
    Bhattacharya D; Belperio PS; Shahoumian TA; Loomis TP; Goetz MB; Mole LA; Backus LI
    Clin Infect Dis; 2017 Jun; 64(12):1711-1720. PubMed ID: 28199525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients.
    Backus LI; Belperio PS; Shahoumian TA; Loomis TP; Mole LA
    Antivir Ther; 2017; 22(6):481-493. PubMed ID: 27934775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
    Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
    BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
    Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
    Liver Int; 2016 Sep; 36(9):1275-83. PubMed ID: 26928927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.
    Del Bello D; Cha A; Sorbera M; Bichoupan K; Levine C; Doyle E; Harty A; Patel N; Ng M; Gardenier D; Odin J; Schiano TD; Fierer DS; Berkowitz L; Perumalswami PV; Dieterich DT; Branch AD
    Clin Infect Dis; 2016 Jun; 62(12):1497-1504. PubMed ID: 26936665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients.
    Backus LI; Belperio PS; Shahoumian TA; Loomis TP; Mole LA
    Hepatology; 2016 Aug; 64(2):405-14. PubMed ID: 27115523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients.
    Shin HP; Burman B; Kozarek RA; Zeigler A; Wang C; Lee H; Zehr T; Edwards AM; Siddique A
    Gut Liver; 2017 Sep; 11(5):711-720. PubMed ID: 28651301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
    Aqel BA; Pungpapong S; Leise M; Werner KT; Chervenak AE; Watt KD; Murphy JL; Ryland K; Keaveny AP; McLemore R; Vargas HE
    Hepatology; 2015 Oct; 62(4):1004-12. PubMed ID: 26096332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis.
    Saxena V; Nyberg L; Pauly M; Dasgupta A; Nyberg A; Piasecki B; Winston B; Redd J; Ready J; Terrault NA
    Hepatology; 2015 Sep; 62(3):715-25. PubMed ID: 26033798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015.
    Yin S; Barker L; White JZ; Jiles RB
    J Manag Care Spec Pharm; 2019 Feb; 25(2):195-210. PubMed ID: 30698086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice.
    Backus LI; Belperio PS; Shahoumian TA; Loomis TP; Mole LA
    Aliment Pharmacol Ther; 2016 Aug; 44(4):400-10. PubMed ID: 27291852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.
    Modi AA; Nazario HE; Gonzales GR; Gonzalez SA
    Aliment Pharmacol Ther; 2018 May; 47(10):1409-1415. PubMed ID: 29569736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study.
    Gaeta GB; Aghemo A; Menzaghi B; D'Offizi G; Giorgini A; Hasson H; Brancaccio G; Palma M; Termini R;
    Medicine (Baltimore); 2018 Jul; 97(27):e11307. PubMed ID: 29979400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience.
    Hlaing NKT; Mitrani RA; Aung ST; Phyo WW; Serper M; Kyaw AMM; Bwa AH; Win KM; Reddy KR
    J Viral Hepat; 2017 Nov; 24(11):927-935. PubMed ID: 28475232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES.
    Butt AA; Yan P; Marks K; Shaikh OS; Sherman KE;
    Aliment Pharmacol Ther; 2016 Oct; 44(7):728-37. PubMed ID: 27459341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
    Steinebrunner N; Sprinzl MF; Zimmermann T; Wörns MA; Zimmerer T; Galle PR; Stremmel W; Eisenbach C; Stein K; Antoni C; Schattenberg JM; Pathil A
    BMC Gastroenterol; 2015 Aug; 15():97. PubMed ID: 26239732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    Sirinawasatien A; Techasirioangkun T
    PLoS One; 2020; 15(2):e0229517. PubMed ID: 32106270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.
    Crittenden NE; Buchanan LA; Pinkston CM; Cave B; Barve A; Marsano L; McClain CJ; Jones CM; Marvin MR; Davis EG; Kuns-Adkins CB; Gedaly R; Brock G; Shah MB; Rosenau J; Cave MC
    Liver Transpl; 2016 May; 22(5):635-43. PubMed ID: 26915588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.